vs
Side-by-side financial comparison of Five9, Inc. (FIVN) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Five9, Inc. is the larger business by last-quarter revenue ($300.3M vs $158.6M, roughly 1.9× Stoke Therapeutics, Inc.). On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 7.8%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $77.3M).
Five9, Inc. is a leading global provider of cloud-native contact center software and solutions. It serves enterprises of all sizes across retail, healthcare, financial services, and technology sectors, offering omnichannel customer engagement tools, AI-powered automation, workforce management, and analytics to boost customer experience and operational efficiency.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
FIVN vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $300.3M | $158.6M |
| Net Profit | — | $112.9M |
| Gross Margin | 55.4% | — |
| Operating Margin | 6.6% | 70.2% |
| Net Margin | — | 71.2% |
| Revenue YoY | 7.8% | 3661.1% |
| Net Profit YoY | — | 528.0% |
| EPS (diluted) | $0.22 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $300.3M | — | ||
| Q3 25 | $285.8M | — | ||
| Q2 25 | $283.3M | — | ||
| Q1 25 | $279.7M | $158.6M | ||
| Q4 24 | $278.7M | $22.6M | ||
| Q3 24 | $264.2M | — | ||
| Q2 24 | $252.1M | — | ||
| Q1 24 | $247.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | $18.0M | — | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $576.0K | $112.9M | ||
| Q4 24 | — | $-10.5M | ||
| Q3 24 | $-4.5M | — | ||
| Q2 24 | $-12.8M | — | ||
| Q1 24 | $-7.1M | — |
| Q4 25 | 55.4% | — | ||
| Q3 25 | 55.0% | — | ||
| Q2 25 | 54.9% | — | ||
| Q1 25 | 55.0% | — | ||
| Q4 24 | 56.0% | — | ||
| Q3 24 | 53.8% | — | ||
| Q2 24 | 53.0% | — | ||
| Q1 24 | 53.6% | — |
| Q4 25 | 6.6% | — | ||
| Q3 25 | 5.6% | — | ||
| Q2 25 | -0.6% | — | ||
| Q1 25 | -1.9% | 70.2% | ||
| Q4 24 | 1.5% | -60.4% | ||
| Q3 24 | -5.8% | — | ||
| Q2 24 | -7.7% | — | ||
| Q1 24 | -8.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | 6.3% | — | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 0.2% | 71.2% | ||
| Q4 24 | — | -46.4% | ||
| Q3 24 | -1.7% | — | ||
| Q2 24 | -5.1% | — | ||
| Q1 24 | -2.9% | — |
| Q4 25 | $0.22 | — | ||
| Q3 25 | $0.21 | — | ||
| Q2 25 | $0.01 | — | ||
| Q1 25 | $0.01 | $1.90 | ||
| Q4 24 | $0.16 | $-0.15 | ||
| Q3 24 | $-0.06 | — | ||
| Q2 24 | $-0.17 | — | ||
| Q1 24 | $-0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $232.1M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $785.8M | $350.1M |
| Total Assets | $1.8B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $232.1M | — | ||
| Q3 25 | $193.4M | — | ||
| Q2 25 | $205.5M | — | ||
| Q1 25 | $370.3M | $274.8M | ||
| Q4 24 | $362.5M | $128.0M | ||
| Q3 24 | $291.0M | — | ||
| Q2 24 | $175.7M | — | ||
| Q1 24 | $240.2M | — |
| Q4 25 | $785.8M | — | ||
| Q3 25 | $775.3M | — | ||
| Q2 25 | $717.4M | — | ||
| Q1 25 | $664.3M | $350.1M | ||
| Q4 24 | $622.2M | $229.0M | ||
| Q3 24 | $565.6M | — | ||
| Q2 24 | $525.9M | — | ||
| Q1 24 | $483.6M | — |
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $2.1B | $406.9M | ||
| Q4 24 | $2.1B | $271.6M | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | $1.9B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $83.6M | $131.8M |
| Free Cash FlowOCF − Capex | $77.3M | $131.7M |
| FCF MarginFCF / Revenue | 25.8% | 83.0% |
| Capex IntensityCapex / Revenue | 2.1% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $201.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $83.6M | — | ||
| Q3 25 | $59.2M | — | ||
| Q2 25 | $35.1M | — | ||
| Q1 25 | $48.4M | $131.8M | ||
| Q4 24 | $49.8M | $-23.2M | ||
| Q3 24 | $41.1M | — | ||
| Q2 24 | $19.9M | — | ||
| Q1 24 | $32.4M | — |
| Q4 25 | $77.3M | — | ||
| Q3 25 | $48.7M | — | ||
| Q2 25 | $31.6M | — | ||
| Q1 25 | $43.7M | $131.7M | ||
| Q4 24 | $40.5M | $-23.2M | ||
| Q3 24 | $26.7M | — | ||
| Q2 24 | $13.1M | — | ||
| Q1 24 | $20.4M | — |
| Q4 25 | 25.8% | — | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 11.1% | — | ||
| Q1 25 | 15.6% | 83.0% | ||
| Q4 24 | 14.5% | -102.7% | ||
| Q3 24 | 10.1% | — | ||
| Q2 24 | 5.2% | — | ||
| Q1 24 | 8.3% | — |
| Q4 25 | 2.1% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.7% | 0.1% | ||
| Q4 24 | 3.3% | 0.2% | ||
| Q3 24 | 5.4% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 4.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 3.29× | — | ||
| Q2 25 | 30.38× | — | ||
| Q1 25 | 84.00× | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
